Senicapoc in Alzheimer's Disease
Eligible age
55–85 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans with early AD. The investigators will study up to 55 patients over 52 weeks, with primary outcomes being Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) scores and blood and cerebrospinal fluid (CSF) markers of neuroinflammation. This pilot study will provide an estimate of treatment effect size on cognitive trajectory, daily function, and brain atrophy.
Sponsor: University of California, Davis
You may qualify if…
- ✓ Age 55-85
- ✓ Fluent in either English or Spanish
- ✓ Willing to be randomized to active drug (10 mg Senicapoc) vs. placebo (3:1 ratio)
- ✓ Clinical Dementia Rating (CDR) global score of 1 or 0.5
- ✓ Education adjusted scores between 12-28 on the Montreal Cognitive Assessment (MoCA) at the Screening visit.
- ✓ A consensus clinical diagnosis of either amnestic Mild Cognitive Impairment (MCI) or mild AD dementia. Diagnoses are made by a comprehensive case conference review for all participants in the ADRC longitudinal cohort and all CADC referrals, resulting in a consensus diagnosis made according to current research criteria. For patients referred from other clinics, the case will be reviewed by a study physician and neuropsychologist and only patients who satisfy criteria for probable AD (McKhann et al 1984) or amnestic MCI (Petersen et al 2004) will be eligible for enrollment.
- ✓ Vision (with or without correction) of at least 20/50 for distant vision
- ✓ All participants will need a study partner informant who has at least 6 hours of contact per week with the participant. The study partners are used to help answer questions on the subject's behalf, since many of them will be impaired and may need assistance with providing accurate information. The study partners are not asked to provide any opinions or judgements about the subjects.
You may not qualify if…
- ✕ Unstable medical illnesses including hepatic insufficiency (elevated ALT, AST, or GGT; or low albumin attributable to liver disease), renal insufficiency (CK-EPI stage 4 or higher, or estimated GFR \<30)
- ✕ Unstable ischemic cardiovascular disease, respiratory failure, moderate or severe congestive heart failure - New York Heart Association class III or IV, cancer, unstable hematologic disease or a life expectancy of \<3 years
- ✕ Use of experimental AD treatments
- ✕ Unable to undergo MRI scanning (e.g. pacemaker, metallic implants, severe claustrophobia)
- ✕ History of chronic psychiatric illness (e.g. schizophrenia), any episode of major depression within last 2 years, or current Geriatric Depression Scale (GDS) \> 6, any recent suicide attempts or suicidal ideation. Subjects with a diagnosis of bipolar disorder may be included if they have been clinically stable for a minimum of 3 years prior to the Screening visit. Clinical stability to be determined by the Principal Investigator.
- ✕ History of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis), head trauma resulting in any persistent cognitive deficit
- ✕ History of alcohol or drug abuse/dependence within the past 5 years
- ✕ Known allergy to chemically related compounds (e.g. clotrimazole)
Where it's recruiting
Sacramento · Walnut Creek
Source: ClinicalTrials.gov · NCT04804241 · last updated 2026-08-17